Skip to main content
First Vaccine Against Breast Cancer

First vaccine against breast cancer

The first breast cancer vaccine begins human trials. The vaccine, which is still in the experimental phase, has been tested in animal models and has shown that in all cases it was able to inhibit the appearance of mammary tumors.

A team of Researchers from Cleveland Clinic's Lerner Research Institute led by Dr. Vincent Tuohy has started the phase I clinical trial in humans to test the first vaccine developed to prevent the triple negative breast cancer (TNBC).

According to 2019 data, in Spain about 33.000 new breast cancers are diagnosed each year, of which it is estimated that around 10% could be TNBC.

Although the breast cancer cure rate It is very high when detected in its earliest stages, some types of breast cancer such as triple negative are more aggressive and more difficult to treat.

The vaccine has been shown in animal models that it was able to prevent the appearance of mammary tumors and stop the growth of existing tumors"

The vaccine, tested so far in animal models, has not only shown that in all cases it was able to prevent the appearance of mammary tumors, but also that it was able to stop the growth of existing tumors in those same animal models in which it was tested.

The research, the details of which have been published in an article in the database of clinical studies, will include the participation of a selection of between 18 and 24 patients who have received treatment for the early stages of triple negative breast cancer in the previous three years and who have been declared tumor free, but who are considered to have a high risk of recurrence.

Our vision has always been to prevent cancer before it develops, so we are excited to go ahead and start vaccinating our first patients. "

The aim of the trial is to determine both the safety and optimal dose of the vaccine in humans, as well as its ability to induce immune responses in patients. If the study allows to demonstrate which is the safe and effective dose, in the next phase of the investigation the number of participants with people in good health will be expanded.

"The transition of our research from the laboratory to patients in the clinic is an important milestone for our program," said Dr. Tuohy, a researcher in the Department of Inflammation & Immunity at Cleveland Clinic's Lerner Research Institute. "Our vision has always been to prevent cancer before it develops, so we are excited to move on and begin vaccinating our first patients."

Women's, by your side

If you need more information or want to make a question, do not hesitate to contact us:

Whatsapp: 34 934 160 606


Make an appointment with our team

    This entry has 0 comments

    Leave an answer

    Your email address will not be published. Required fields are marked with *

    This site uses cookies for you to have the best user experience. If you continue to browse you are giving your consent to the acceptance of the aforementioned cookies and acceptance of our Cookies policy, Click the link for more information.plugin cookies

    Notice of cookies